COMMUNIQUÉS West-GlobeNewswire
-
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
19/03/2024 - 09:00 -
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
19/03/2024 - 10:00 -
Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office
19/03/2024 - 10:00 -
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
19/03/2024 - 11:00 -
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19/03/2024 - 11:00 -
Unauthorized Access to Employee Mobile Devices Leads to More Than Half of Organizations Experiencing a Data Breach, New Report Finds
19/03/2024 - 11:00 -
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
19/03/2024 - 11:01 -
ObsEva Announces Update on Board of Directors
19/03/2024 - 07:00 -
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
19/03/2024 - 07:00 -
IBA signe un contrat pour l'installation d'une solution d'irradiation Be-Efficient en Allemagne
19/03/2024 - 07:00 -
IBA signs contract to install a Be-Efficient irradiation solution in Germany
19/03/2024 - 07:00 -
Mendus to present NK cell program progress at the Innate Killer Summit
19/03/2024 - 08:00 -
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
19/03/2024 - 04:58 -
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
18/03/2024 - 20:16 -
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
18/03/2024 - 20:41 -
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
18/03/2024 - 21:00 -
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
18/03/2024 - 21:00 -
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18/03/2024 - 21:01 -
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
18/03/2024 - 21:01
Pages